Loading...
Despite the general effectiveness of metabolic surgery for patients with severe obesity, as many as one quarter have suboptimal weight loss. In this British study, researchers tested liraglutide as an adjunct for 70 patients with suboptimal weight loss (i.e., <20% of body weight) following surgery and suboptimal GLP-1 response to eating (i.e., ≤2-fold increase); 65 had undergone sleeve gastrectomy and 5 had undergone Roux-en-Y gastric bypass. Mean weight loss following surgery was 7% from a mean baseline of 265 pounds. Patients were randomized to liraglutide 3.0 mg daily by subcutaneous injection or saline control. The daily dose started at 0.6 mg and was increased each week by 0.6 mg as tolerated. All patients were counseled to adopt a 500…